Remodeling of the left ventricular myocardium in patients with chronic kidney disease and arterial hypertension
https://doi.org/10.34215/1609-1175-2021-2-52-56
Abstract
Objective: The estimation of the causes of remodeling left ventricular myocardium among patients having arterial hypertension (AH) and chronic kidney disease.
Methods: 98 patients having AH were examined. Hypertrophy of the left ventricular (LV) was diagnosed when LV myocardium mass index was more than 115 g/м2 for men and more than 95 g/м2 for women. The formula to estimate the speed of glomerular filtration CKD-EPI was used to define the degree of kidney dysfunction.
Results: The signs of LV myocardial remodeling were observed among 43 patients having AH (43.8 %). High prevalence of the obesity and hypertrophy of the left ventricular was observed among women (71.4 % compared with 18.7 % among men).
Conclusions: LV myocardial hypertrophy is associated with the length of AH anamnesis. Hypertrophy unfavorable in terms of cardiovascular complications was more frequently registered as concentric. Also high prevalence of the chronic kidney disease in phases С2, С3а and С3b was observed among patients having AH. It increases the risk of unfortunate prognosis and requires active preventive measures and the correction of drug therapy to prevent fatal cardiovascular cases.
About the Authors
E. F. Yakuhnaya
Pacific State Medical University;
Far Earsten District Medical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
MD, PhD, associate professor, Institute of Simulation and Accreditation Technologies
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
E. V. Solyanik
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, professor, Institute of Simulation and Accreditation Technologies
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
V. V. Hitrina
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, associate professor, Institute of Simulation and Accreditation Technologies
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
E. I. Shevchenko
Pacific State Medical University
Russian Federation
Russian Federation
MD, student of the training program for highly qualified personnel in the residency
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
T. E. Abrosimova
Far Earsten District Medical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
MD
161 Stoletiya Vladivostokf Ave., Vladivostok, 690022, Russian Federation
E. L. Shuvalova
Far Earsten District Medical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
MD
161 Stoletiya Vladivostokf Ave., Vladivostok, 690022, Russian Federation
References
1. Volpe M, Battistoni A, Tocci G. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens. 2012;30:1056–64.
2. Polozova EI, Puzanova EV, Seskina AA, Nefedov NS. The relationship of risk factors and heart remodeling in patients with metabolic syndrome and arterial hypertension. Medical Advice. 2020;21:19–25 (In Russ).
3. Tsai WC, Wu. HY, Peng YS. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):792–9.
4. Jafar TH, Stark PC, Schmid CH. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin- converting enzyme inhibition: a patient-level metaanalysis. Ann Intern Med. 2003;139:244–52.
5. Sim JJ, Shi J, Kovesdy CP. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64(6):588–597.
6. Bakris GL, Saraèdis PA, Weir MR. Renal outcomes with different exed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecieed secondary analysis of a randomized controlled trial. Lancet. 2010;375:1173–81.
7. Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med. 2004;351:1296–305.
8. Manjunath G, Tighiouart H, Ibrahim HN. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41(1):47–55.
9. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD- EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307(18):1941–51.
10. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3 (Suppl):1–150.
11. Pyankina OV, Tatarinsev PB, Ragozin ON. Remodeling of left ventricular myocardium in the progression of chronic kidney disease. Ulyanovskii Medical and Biological Jornal. 2012;3:13–20 (In Russ).
12. Balanova YA, Shalnova SA, Deev AD, Imaeva AE, Kontsevaya AV, Muromtseva GA, et al. Obesity in Russian populstion – prevalence and association with the non-communicable diseases risk factors. Russian Jornal of Cardiology. 2018;23(6):123–30 (In Russ).
Review
For citations:
Yakuhnaya E.F., Solyanik E.V., Hitrina V.V., Shevchenko E.I., Abrosimova T.E., Shuvalova E.L. Remodeling of the left ventricular myocardium in patients with chronic kidney disease and arterial hypertension. Pacific Medical Journal. 2021;(2):52-56. (In Russ.) https://doi.org/10.34215/1609-1175-2021-2-52-56
Views:
285
Email this article 